Arvinas (NASDAQ:ARVN) Upgraded by Zacks Research to “Strong-Buy” Rating

Zacks Research upgraded shares of Arvinas (NASDAQ:ARVN) from a hold rating to a strong-buy rating in a report issued on Wednesday,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. Barclays increased their price target on Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Weiss Ratings cut Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. Stephens reiterated an “overweight” rating and issued a $18.00 price objective on shares of Arvinas in a research report on Wednesday, June 3rd. Wells Fargo & Company reissued an “equal weight” rating and set a $11.00 target price (down from $15.00) on shares of Arvinas in a research note on Tuesday. Finally, Citigroup raised their target price on shares of Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $14.90.

Arvinas Stock Up 3.3%

ARVN opened at $8.68 on Wednesday. Arvinas has a 12 month low of $6.05 and a 12 month high of $14.51. The company has a fifty day simple moving average of $8.06 and a 200 day simple moving average of $10.25. The stock has a market cap of $560.03 million, a P/E ratio of 86.81 and a beta of 1.71.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of ($0.37) by $2.95. The business had revenue of $249.70 million for the quarter, compared to the consensus estimate of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The firm’s revenue was up 1014.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.84) EPS. On average, equities research analysts expect that Arvinas will post -2.39 earnings per share for the current fiscal year.

Insider Buying and Selling at Arvinas

In other news, insider Noah Berkowitz sold 11,108 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $110,413.52. Following the sale, the insider directly owned 191,395 shares in the company, valued at $1,902,466.30. The trade was a 5.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Andrew Saik sold 5,696 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $8.16, for a total value of $46,479.36. Following the transaction, the chief financial officer directly owned 187,432 shares of the company’s stock, valued at $1,529,445.12. This represents a 2.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 41,728 shares of company stock valued at $402,649 in the last 90 days. 7.30% of the stock is currently owned by company insiders.

Institutional Trading of Arvinas

A number of hedge funds and other institutional investors have recently made changes to their positions in ARVN. Bank of New York Mellon Corp bought a new stake in shares of Arvinas in the second quarter worth $2,119,000. State of Wyoming acquired a new position in Arvinas during the second quarter worth $125,000. GSA Capital Partners LLP bought a new position in Arvinas in the second quarter valued at $1,182,000. Assenagon Asset Management S.A. grew its position in Arvinas by 138.2% in the second quarter. Assenagon Asset Management S.A. now owns 68,456 shares of the company’s stock valued at $569,000 after purchasing an additional 39,720 shares in the last quarter. Finally, Quantinno Capital Management LP grew its position in Arvinas by 12.5% in the first quarter. Quantinno Capital Management LP now owns 74,540 shares of the company’s stock valued at $790,000 after purchasing an additional 8,295 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas News Roundup

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Arvinas received a Zacks Rank #1 (Strong Buy), reflecting improved expectations for its earnings outlook and potentially supporting near-term buying interest. Arvinas Upgraded to Strong Buy
• Positive Sentiment: HC Wainwright materially raised its FY2026 EPS forecast to a loss of $0.67 from a loss of $3.98, while also improving estimates for FY2027 through FY2030. Its FY2030 forecast moved into profitability at $0.07 per share, suggesting better long-term operating prospects. Arvinas Analyst Estimates
• Positive Sentiment: BTIG Research assigned Arvinas a “Buy” rating, adding to the bullish analyst support. Arvinas Earns Buy Rating from BTIG
• Positive Sentiment: Arvinas’ latest quarterly results substantially exceeded expectations, with $249.7 million in revenue versus a $60.7 million consensus estimate and EPS of $2.58 versus an expected loss. Revenue increased more than tenfold year over year, providing a strong fundamental backdrop. Arvinas Trading Higher on Strong Earnings
• Neutral Sentiment: HC Wainwright lowered its Q3 and Q4 2026 EPS forecasts to losses of $1.20 and $1.19, respectively, but raised most full-year estimates. The mixed revisions indicate near-term profitability remains pressured even as the longer-term outlook improves.
• Negative Sentiment: Wells Fargo downgraded Arvinas to “Equal Weight,” signaling reduced conviction in additional upside and contributing to selling pressure. Arvinas Rating Lowered to Equal Weight
• Negative Sentiment: Shares fell sharply following an analyst downgrade, highlighting the stock’s sensitivity to changes in Wall Street sentiment. Arvinas Shares Down on Analyst Downgrade

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.